Patients’ and Consumers’ Working Party (PCWP)

The Patients' and Consumers' Working Party was created to provide recommendations to the EMEA and its human scientific committees on all matters of direct or indirect interest to patients in relation to medicinal products.

  • The Working Party began in January 2006

 
Composition of Working Party

  • International Alliance of Patients’ Organizations (IAPO)
  • European Patients’ Forum (EPF)
  • European Organisation for Rare Diseases (EURORDIS)
  • European Cancer Patient Coalition (ECPC)
  • The European Consumers’ Organisation (BEUC)
  • International Patient Organisation for Primary Immunodeficiencies (IPOPI)
  • European Public Health Alliance (EPHA)
  • European Federation of Neurological Associations (EFNA)
  • European AIDS Treatment Group (EATG)
  • International Diabetes Federation (IDF)
  • representatives from the EMEA human scientific committees (CHMP, COMP and HMPC)
  • representatives from the EMEA secretariat.

 
Lise Murphy is a Eurordis nominated Patient Representative

Current mandate: February 2007 – 2010

Swedish Marfan Syndrome
 
 
 
 
 
 
François HouÿezFrançois Houÿez is a Eurordis nominated Patient Representative

Current mandate: February 2007 – 2010
 
 
 
 
 
 
 
 
The EMEA Human Scientific Committees Working Party with Patients and Consumers Organisations (PCWP) is established to provide recommendations to the EMEA and its Human Scientific Committees on all matters of direct or indirect interest to patients in relation to medicinal products including, but not limited to the tasks defined below:
 

  • Contribute to the implementation Final Recommendations and Proposals for Action of the former EMEA/CHMP Working Group with Patients Organisations (Doc.  Ref. EMEA/161660/2005).
  • Contribute to the provision of information adapted to patients and consumers needs.
  • Contribute to the development of appropriate communication tools.
  • Contribute to increase awareness of patients in relation to the use of medicines.
  • Contribute to promote a rational use of medicines.
  • Contribute to the development and the training of a network of Patients’ and Consumers’ Organisations.
  • Define performance indicators for monitoring of implementation of actions.
  • Provide general advice in relation to product specific matters, at the request of the EMEA Human Scientific Committees.
  • Liaise with interested parties (health-care professionals’ organisations, learned societies, academia, pharmaceutical industry) (See section VI. Rules of procedure point 9).
  • Set up drafting groups, when necessary (see section VI. Rules of Procedure, point 4).
  • Liaise with other Working Parties on matters of interest to patients in relation to medicinal products.
  • Provide advice to the CMD (h) upon request, on matters of interest to patients in relation to medicinal products.

 

Page created: 02/02/2010
Page last updated: 02/02/2010